Skip to main content
. 2022 Dec 1;13:1003975. doi: 10.3389/fimmu.2022.1003975

Figure 2.

Figure 2

JAM-A is expressed on mononuclear phagocytes infiltrating human and mouse tumors. (A) JAM-A expression on endothelial cells and immune cells in LLC tumors (n=4-5). 21 days post-engraftment, 1678 ± 212mm3 tumor volume. (B) Same as (A) in Py8119 tumors (n=4-6). 32 days post-engraftment, 1199 ± 114mm3 tumor volume. (C) Representative histogram of JAM-A expression on blood monocytes, tumor-infiltrating monocytes and tumor-associated macrophages in LLC and Py8119 tumors. (D) Fold change of JAM-A expression on macrophages, monocytes and endothelial cells in Py8119 tumors of Il1b -/- mice compared to Il1b +/+ mice (n=6). 35 days post-engraftment, tumor burden is shown in Supplementary Figure 3 . (E) JAM-A expression on endothelial cells and immune cells in human non-small cell lung cancer (NSCLC) (n=3). JAM-A expression was determined using flow cytometry. ΔMFI: Delta Median Fluorescent Intensity (MFI) = MFI of anti-JAM-A-stained sample minus MFI of isotype control-stained sample. Bar graphs show mean and SEM.